MAP CARD SD GPS Navigation Sonata 17 16 15 96554-C2010 96554 OEM C2010 Car GPS Software & Maps


  1. Home
  2. MAP CARD SD GPS Navigation Sonata 17 16 15 96554-C2010 96554 OEM C2010
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
96554-C2010 15 16 17 Sonata Navigation GPS SD CARD MAP 96554 C2010 OEM
Condition: New Country/Region of Manufacture: Unknown
Software Format: SD Card Type: GPS Map & Software
Brand:

Factory/OEM

Manufacturer Part Number:

96554 C2010

Warranty: 30 DAYS
published on tue nov 09 2021

MAP CARD SD GPS Navigation Sonata 17 16 15 96554-C2010 96554 OEM C2010 Car GPS Software & Maps

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

MAP CARD SD GPS Navigation Sonata 17 16 15 96554-C2010 96554 OEM C2010 Car GPS Software & Maps

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.

509
1.2k
EVGENIA.RU RSS